| dbo:abstract
|
- سيكسوتوموماب هو جسم مضاد وحيد النسيلة لعلاج الأورام الصلبة، تطورته شرطة . (ar)
- Cixutumumab (IMC-A12) is a human monoclonal antibody for the treatment of solid tumors. This drug was developed by ImClone Systems, since acquired by Eli Lilly, using phage display technology from . It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the ligand IGF-1 and subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis. (en)
- Il 'Cixutumumab nome commerciale IMC-A12 è un anticorpo monoclonale di tipo umano, che viene utilizzato per il trattamento di forme di tumori solidi.Esso è stato sviluppato dalla Systems Inc.. Il farmaco agisce sull'antigene (human insulin-like growth factor-1 receptor) (IGF-1R), che è implicato in fenomeni di tumorigeninesi e metastasi. (it)
|
| dbo:casNumber
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 6224 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chemspiderid
| |
| dbp:h
| |
| dbp:kegg
| |
| dbp:mabType
| |
| dbp:n
| |
| dbp:o
| |
| dbp:routesOfAdministration
| |
| dbp:s
| |
| dbp:source
| |
| dbp:target
| |
| dbp:type
| |
| dbp:unii
| |
| dbp:verifiedfields
| |
| dbp:verifiedrevid
| |
| dbp:watchedfields
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- سيكسوتوموماب هو جسم مضاد وحيد النسيلة لعلاج الأورام الصلبة، تطورته شرطة . (ar)
- Il 'Cixutumumab nome commerciale IMC-A12 è un anticorpo monoclonale di tipo umano, che viene utilizzato per il trattamento di forme di tumori solidi.Esso è stato sviluppato dalla Systems Inc.. Il farmaco agisce sull'antigene (human insulin-like growth factor-1 receptor) (IGF-1R), che è implicato in fenomeni di tumorigeninesi e metastasi. (it)
- Cixutumumab (IMC-A12) is a human monoclonal antibody for the treatment of solid tumors. This drug was developed by ImClone Systems, since acquired by Eli Lilly, using phage display technology from . It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the ligand IGF-1 and subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell p (en)
|
| rdfs:label
|
- سيكسوتوموماب (ar)
- Cixutumumab (en)
- Cixutumumab (it)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
